EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune Checkpoint Inhibitor Therapy for Kidney Transplant Recipients – A Review of Potential Complications and Management Strategies

Elena Bianca Barbir, Samer Abdulmoneim, Arkadiusz Z Dudek, Aleksandra Kukla

Transplant International · 2024

DOI: 10.3389/ti.2024.13322 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplant International, 2024. Verfasst von Elena Bianca Barbir und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States. Hauptthemen laut MEDLINE: Kidney Transplantation, Immune Checkpoint Inhibitors, Graft Rejection. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitor (ICI) therapy has enabled a paradigm shift in Oncology, with the treatment of metastatic cancer in certain tumor types becoming akin to the treatment of chronic disease. Kidney transplant recipients (KTR) are at increased risk of developing cancer compared to the general population. Historically, KTR were excluded from ICI clinical trials due to concern for allograft rejection and decreased anti-tumor efficacy. While early post-marketing data revealed an allograft rejection risk of 40%–50%, 2 recent small prospective trials have demonstrated lower rates of rejection of 0%–12%, suggesting that maintenance immunosuppression modification prior to ICI start modulates rejection risk. Moreover, objective response rates induced by ICI for the treatment of advanced or metastatic skin cancer, the most common malignancy in KTR, have been comparable to those achieved by immune intact patients. Non-invasive biomarkers may have a role in risk-stratifying patients before starting ICI, and monitoring for rejection, though allograft biopsy is required to confirm diagnosis. This clinically focused review summarizes current knowledge on complications of ICI use in KTR, including their mechanism, risk mitigation strategies, non-invasive biomarker use, approaches to treatment of rejection, and suggestions for future directions in research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationImmune Checkpoint InhibitorsGraft RejectionHumansImmunosuppressive AgentsSkin NeoplasmsTransplant Recipients

Stichwörter der Autor:innen

biomarkersimmunologyimmunotherapykidney transplantoncologyrejection risk

Substanzen

Immune Checkpoint InhibitorsImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States.
  • Department of Surgery, Mayo Clinic, Rochester, MN, United States.
  • Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States.

Zitieren

APA

Barbir, E. B., Abdulmoneim, S., Dudek, A. Z., & Kukla, A. (2024). Immune Checkpoint Inhibitor Therapy for Kidney Transplant Recipients – A Review of Potential Complications and Management Strategies. Transplant International. https://doi.org/10.3389/ti.2024.13322

Vancouver

Barbir EB, Abdulmoneim S, Dudek AZ, Kukla A. Immune Checkpoint Inhibitor Therapy for Kidney Transplant Recipients – A Review of Potential Complications and Management Strategies. Transplant International. 2024. doi:10.3389/ti.2024.13322

BibTeX
@article{Barbir2024,
  author = {Barbir, Elena Bianca and Abdulmoneim, Samer and Dudek, Arkadiusz Z and Kukla, Aleksandra},
  title = {Immune Checkpoint Inhibitor Therapy for Kidney Transplant Recipients – A Review of Potential Complications and Management Strategies},
  journal = {Transplant International},
  year = {2024},
  doi = {10.3389/ti.2024.13322}
}
Kostenlos starten →